Similarly, a peptide derived from the Cx43 C-terminal (TAT-Cx43 266-283) has been demonstrated to reduce the cancer stem cell (CSC) phenotype by inhibiting c-Src in patient-derived glioma models [103,104] and in vivo mouse models [104]. This evidence concerns the gene GJA1 and central nervous system cancer.